4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)-oxy)-1-methyl-6-(piperidin-1-yl)pyrimidin-2(1H)-one

ID: ALA3794546

Chembl Id: CHEMBL3794546

PubChem CID: 121448333

Max Phase: Preclinical

Molecular Formula: C24H21ClF5N3O3

Molecular Weight: 529.89

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1c(N2CCCCC2)cc(OCc2cc(F)c(Oc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)nc1=O

Standard InChI:  InChI=1S/C24H21ClF5N3O3/c1-32-21(33-7-3-2-4-8-33)12-20(31-23(32)34)35-13-14-9-18(26)22(19(27)10-14)36-15-5-6-17(25)16(11-15)24(28,29)30/h5-6,9-12H,2-4,7-8,13H2,1H3

Standard InChI Key:  RVVACDYMBPVRNL-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3794546

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 529.89Molecular Weight (Monoisotopic): 529.1192AlogP: 6.09#Rotatable Bonds: 6
Polar Surface Area: 56.59Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 0.99CX LogP: 6.01CX LogD: 6.01
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.36Np Likeness Score: -1.19

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source